Patients with myocardial bridges are often asymptomatic but this anomaly may be associated with exertional angina, acute coronary syndromes, cardiac arrhythmias, syncope or even sudden cardiac death. This review presents our understanding of the pathophysiology of myocardial bridging and describes prevailing diagnostic modalities and therapeutic options for this challenging clinical entity.
Introduction
Coronary arteries that tunnel through the myocardium are seen as often as 40-80% on autopsy; however, functional myocardial bridging is less commonly observed on angiography (0.5-16%) and can range from 4 to 80 mm in length (1) (2) (3) (4) . Although myocardial bridges can be found in any epicardial artery, 67-98% occur in the left anterior descending coronary artery (LAD) (5, 6) . Bridges have been described as superficial or deep based on three observations: 1) they range from 0.3 to 28 mm in depth (4, 5) , 2) anatomically they consist of either superficial myocardial fibers that traverse over the LAD or deep fibers that encircle the LAD (5,7) and 3) bridges >5 mm deep are less amenable to surgical myotomy (8) . The hemodynamic impact of myocardial bridging depends on the thickness and length of the bridge, orientation of the bridge relative to myocardial fibers and presence of loose connective or adipose tissue around the bridged segment.
Pathophysiology
Autopsy and intravascular ultrasound (IVUS) studies demonstrate that the intramural and distal segments of bridged vessels remain free from atherosclerotic disease while the proximal segment of the vessel is prone to developing atherosclerosis (9, 10) . Biomechanical forces may explain these observations. At the entrance of a myocardial bridge, fluid mechanics play an important role in plaque formation as disturbed near-wall blood flow patterns are a central factor in the spatial distribution of atherosclerosis (11, 12) . Low and oscillatory wall shear stress (WSS) are associated with increased vascular cell adhesion molecule-1 expression (11, 13) and reactive oxygen species production (14) , as well as the development of a pro-atherogenic endothelial cell phenotype (12) . Indeed, autopsy studies have demonstrated that coronary segments immediately proximal to myocardial bridges, where WSS is low, demonstrate structurally dysfunctional, flat and polygonal endothelial cells whereas endothelial cells lining bridged segments, where WSS is physiologic or high, are structurally intact (15) . Clinical studies in patients with mild atherosclerosis but without bridging have demonstrated greater plaque progression in segments with low WSS compared to physiologic or high WSS (16) . In a case-control series comparing patients with bridging to controls (17) , wall shear rate, the velocity gradient perpendicular to the wall, was found to be lower proximal to the bridge as compared to within the bridge. Figure 1 represents a computational fluid dynamics model at end-systole of the LAD in a patient with a symptomatic myocardial bridge revealing an area of relative low WSS proximal and distal to the bridge and high WSS within the bridge. Enhanced myocardial compression at the bridge entrance also results in abrupt breakage of the propagating antegrade systolic wave, disrupting blood flow patterns, exacerbating the low WSS, and intensifying endothelial injury and the stimuli for plaque formation (18) . Another proposed mechanism of plaque formation proximal to a myocardial bridge involves solid mechanical forces that result from the motion and deformation of the coronary tree and myocardial material properties. Specifically, compression within the bridge and severe vessel angulation at the junction of the bridge result in a heterogeneous stress field in the proximal segment. The induced stresses are hypothesized to be conducive to plaque development and possible fissuring in the proximal segments (18) .
Within the bridge, increased mechanical loads likely contribute to constrictive vascular remodeling as an attempt to restore loads to homeostatic levels (19) . These mechanisms are amplified with diastolic dysfunction that occurs with left ventricular hypertrophy. In addition, separation of the bridged segment from perivascular adipose tissue in the epicardium that is associated with pro-inflammatory cytokines and adipokines may be a protective mechanism against the development of atherosclerosis (20) . These factors likely contribute to plaque formation proximal to myocardial bridges and exert an atheroprotective role within the bridge. The relative lack of atherosclerosis observed distal to myocardial bridges despite presence of low WSS is not well understood. Clearly, complex and dynamic biomechanical factors influence the blood flow within and at the exit of the bridge that in aggregate appear to attenuate the pro-atherosclerotic stimulus of low WSS observed distal to the bridge.
Additional pathophysiologic changes can induce symptoms of myocardial ischemia in previously asymptomatic patients (figure 2). First, increasing left ventricular diastolic dysfunction associated with aging, hypertension, and coronary atherosclerosis can exacerbate the supply-demand mismatch imposed by the bridge. Second, left ventricular hypertrophy development can increase compression and reduce the coronary microvascular reserve. Third, coronary vasospasm, microvascular dysfunction, or endothelial dysfunction related to cardiovascular risk factors combined with the bridge can result in myocardial ischemia. Fourth, plaque development proximal to the bridge can augment coronary obstruction by the bridge. Fifth, the negative remodeling within the bridge can reduce myocardial flow. Each of these factors can contribute to a varying degree to the development of symptoms in patients with myocardial bridging.
More recently, it has been recognized that myocardial ischemia is not purely related to systolic vascular compression. Indeed, systolic vessel compression has been shown to persist into mid-to-late diastole (2) . The hemodynamic disturbance imposed by this persistent diastolic luminal narrowing was corroborated by increases in both average peak-flow velocity and average diastolic peak-flow velocity, with only minor changes in systolic blood flow within the bridged segment of the coronary artery. These data suggest that both systolic and diastolic flow impairment contribute to myocardial supply to demand mismatch in patients with myocardial bridging.
Clinical Presentation
Although myocardial bridging can be an incidental finding on angiography or autopsy, symptomatic patients who have myocardial bridges as their only cardiac abnormality may present with myocardial ischemia (21) , acute coronary syndromes (22) (23) (24) , coronary spasm (21, 25) , exercise-induced dysrhythmias like supraventricular tachycardia (24) , ventricular tachycardia (26, 27) or atrioventricular conduction block (28), myocardial stunning (29), transient ventricular dysfunction (30) , syncope (24, 27) or even sudden death (31, 32) .
Diagnosis
A number of diagnostic modalities have been deployed to investigate the anatomic and physiologic significance of myocardial bridging ( Table 1 ). Because of the lack of a true gold standard for diagnosing myocardial bridging, the reported diagnostic accuracies are variable.
Non-Invasive Diagnostic Techniques
Multiple-slice computed tomography (MSCT), stress single photon emission computed tomography (SPECT) and stress echocardiography have been used in the diagnosis of myocardial bridging. MSCT defines bridges as segments surrounded by myocardium (33) . Recent developments allowing for physiologic assessment by MSCT may enhance its diagnostic utility for identifying hemodynamically significant bridges. Stress SPECT can detect reversible myocardial perfusion defects in patients with myocardial bridging and relate the amount of ischemia to the degree of systolic luminal narrowing (34, 35) . Contrast stress echocardiography has been reported for myocardial bridge detection but is less validated (36) .
Invasive Diagnostic Techniques
On angiography, diagnosis depends on the diameter change between systole and diastole within the bridged coronary segment. A significant "milking effect" (Figure 3 ) is present when there is ≥70% reduction in minimal luminal diameter (MLD) during systole and persistent ≥35% MLD reduction during mid-to-late diastole (2) . Systolic narrowing at the bridge can be accentuated by intracoronary nitroglycerin injection by vasodilating adjacent non-bridged coronary segments ( Figure 4 ) (9,37).
Adjunctive intravascular imaging and physiology can contribute to our clinical evaluation and understanding of the complex pathophysiology of bridging. On IVUS, the characteristic finding is the "half-moon" sign: an echolucent area present only between the bridged coronary segment and epicardial tissue that persists throughout the cardiac cycle ( Figure 5 ) (9) . Additionally, IVUS can characterize sub-angiographic atherosclerosis proximal to bridges.
Coronary physiologic measurements across a myocardial bridge during pharmacologic infusion can be valuable for 1) evaluation of the hemodynamic significance of fixed obstruction associated with the bridge, 2) simulation of dynamic myocardial obstruction that could contribute to ischemic symptoms and 3) unmasking concomitant endothelial dysfunction or coronary vasospasm within the bridged segment that could also be clinically relevant. The bridged segment produces a distinctive flow velocity called the "finger tip" phenomenon ( Figure 6 ). The abrupt velocity acceleration in early diastole results from a decrease in distal microvascular resistance as the myocardium untwists during isovolumetric relaxation concomitant with continuing myocardial compression of the bridged coronary segment. Rapid deceleration in velocity ensues as the bridge muscle relaxes and the lumen cross-sectional area increases. Velocity plateau occurs when the artery has fully reopened (1, 18) .
For the evaluation of hemodynamically significant stenoses, fractional flow reserve (FFR) can be measured (38) . A patient with a myocardial bridge with an FFR <0.75 likely has ischemia associated with that bridge. As in non-bridged patients, there is a grey zone of ischemia from FFR 0.75-0.80. For a patient with an abnormal but non-ischemic FFR (>0.80), intravenous dobutamine administration can lead to higher pressure gradients (and sometimes ventricularization of the distal pressure tracing) and reproduction of their angina symptoms, which would then suggest a clinically significant myocardial bridge (39) . If concomitant velocity data are available, higher average peak velocity with infusion of dobutamine ( Figure 7B ) as compared to adenosine ( Figure 7A ) in association with the higher pressure gradients suggests further luminal narrowing, lending further support to the clinical significance of the myocardial bridge. Finally, vasoconstriction with intracoronary acetylcholine infusion (off-label use) can unmask concomitant endothelial dysfunctional or coronary vasospasm.
Classification
The Schwarz classification (Table 2) can serve as a guide for directing therapy for patients with myocardial bridging since it has been linked to clinical outcomes following pharmacological and invasive interventions (40) . Schwarz type A patients need no treatment, whereas types B and C patients show significant symptomatic improvement with β-blockers or calcium channel blockers at five-year follow-up. Type C patients refractory to medical therapy may be considered for revascularization of the myocardial bridge.
Management
Treatment of symptomatic patients with myocardial bridging consists primarily of pharmacologic therapy although percutaneous coronary intervention (PCI), myotomy, or coronary artery bypass grafting surgery (CABG) can be considered for selected patients refractory to maximal medical therapy.
A: Pharmacological Therapy
Aggressive risk factor modification is advocated and antiplatelet therapy should be considered in patients with myocardial bridging as they are at increased risk of developing atherosclerosis. One approach to individualizing the need for antiplatelet therapy would be to perform MSCT to identify subclinical atherosclerosis. For symptomatic patients, βblockers remain the mainstay of treatment and relieve the hemodynamic disturbance caused by the myocardial bridge by decreasing heart rate, increasing diastolic coronary filling period, and decreasing contractility and compression of the coronary arteries (2, 41) . Calcium channel blockers are also frequently used and, in addition to the aforementioned pharmacologic effects of β-blockers, may have vasodilatory effects that might be beneficial in patients with concomitant vasospasm. Head-to-head comparison of β-blockers and calcium channel blockers or randomized clinical trials of outcome benefit of β-blockers are not available.
In contrast, pure vasodilating agents such as nitroglycerin should be used cautiously in patients with myocardial bridges. Although nitrates have antispasmodic properties and can decrease preload, they can worsen symptoms by intensifying systolic compression of the bridged segment and vasodilating segments proximal to the bridge (figure 4), thereby exacerbating retrograde flow in the proximal segment and reducing the myocardial ischemic threshold (9, 37) . Vasodilators should thus be avoided unless there is significant co-existing coronary vasospasm.
B: Percutaneous Coronary Intervention
Stent implantation in symptomatic patients with myocardial bridges can ameliorate peak intracoronary systolic pressure and vessel compression, normalize flow and abolish symptoms (42) ; however, concerns regarding perforation during stent deployment (21, 43) , stent fracture (44) , in-stent restenosis (44) (45) (46) (47) (48) and stent thrombosis (49) have limited their use in this condition. Investigations focusing on in-stent restenosis are summarized in Table  3 and suggest two conclusions: 1) stent implantation in patients with symptomatic myocardial bridges result in high rates of early in-stent restenosis which may be related to bridge-associated decreased lumen area and 2) compared to PCI with bare metal stents (BMS), PCI with drug-eluting stents (DES) have lower rates of target vessel revascularization (TVR).
Higher restenosis rates were demonstrated in patients undergoing PCI with BMS for symptomatic isolated myocardial bridging in one prospective study of 11 patients which reported early in-stent restenosis requiring TVR in 4 patients (45) and in another investigation comparing a similar cohort of 12 patients to 39 patients who underwent BMS implantation for atherosclerotic lesions in the LAD (46) . While DES implantation results in lower TVR rates than BMS implantation, restenosis still occurs more frequently in PCI for symptomatic myocardial bridging than in PCI for atherosclerotic lesions. A small study that compared implantation of DES (n=8) versus BMS (n=4) in symptomatic patients refractory to maximal medical therapy reported lower TVR rates in the DES cohort than in the BMS group, but both groups had higher rates relative to historical controls (47) . Another investigation evaluated PCI with predominantly DES in 70 patients with both myocardial bridges and LAD lesions and divided them into two cohorts based on whether the implanted stents ended proximal to a myocardial bridge or extended into the bridged segment. The TVR rate was significantly higher in patients with stents extending into the bridge compared to patients with stents ending proximal to the myocardial bridge (29% vs. 3%) (48) . Interestingly, minimum stent cross-sectional area was also significantly smaller for stents extending into the bridged segment as opposed to those that ended proximal to the bridge (4.8 mm 2 vs. 5.8 mm 2 ). A recent prospective study of PCI with DES for symptomatic isolated myocardial bridging reported 3/15 patients requiring revascularization within 6 months post-procedure but no further complications (43) .
Any rationale for PCI in selected myocardial bridge patients would be to treat plaque proximal to the bridge as well as the negative remodeling and dynamic obstruction within the bridged segment. While contemporary metallic stent platforms can provide sufficient scaffolding to achieve adequate diastolic and systolic flow, sustained stress over time may result in stent fracture, restenosis, or thrombosis. Concerns have also been raised about the radial strength of bioabsorbable stents. Future bioabsorbable scaffolds could be designed with sufficient radial strength to safely achieve greater acute luminal gain in the intramyocardial artery while withstanding the systolic compression pressure during the bioabsorption phase, which after resorption could leave behind a much larger lumen supported by a residual thin fibrous endoluminal layer. Whether scaffolds with these biomechanical properties can be developed and withstand the scrutiny of angiographic and outcome studies remain to be seen.
Taken together, although there are no randomized controlled trials of optimal medical therapy versus optimal medical therapy and contemporary PCI with DES, medical therapy appears to be superior to PCI. Ischemia guided revascularization using DES may be considered on a case-to-case basis for symptomatic patients refractory to maximal medical therapy and who are not optimal surgical candidates.
C: Surgical Treatment
Surgical intervention involves either supraarterial myotomy or CABG. In a typical myotomy case (Figure 8) , the cardiac muscle is dissected carefully and completely. Potential complications of myotomy include wall perforation, ventricular aneurysm formation and post-operative bleeding. Conversely, the major concern of CABG with regards to myocardial bridges is graft failure.
Studies investigating the effectiveness of myotomy or CABG in patients with symptomatic bridging refractory to medical therapy are summarized in Table 4 . Two retrospective studies on myotomy described overall successful operations; however, one series reported accidental right ventricular wall perforation in 2/9 patients (50) and the other study reported that 1/26 patients underwent CABG for post-operative angina with LAD narrowing (51) . Regarding CABG, one investigation reported no complications (52) while the second described 6/39 patients with recurrent angina and 15/39 patients with graft occlusions on follow-up (53) . Grafting with the LIMA was more likely to result in occlusion compared to grafting with the saphenous vein (12 vs. 3 patients), leading the authors to conclude that grafting with the saphenous vein was preferable. This is in contrast to a previous report recommending the LIMA as the preferred graft for CABG (4) .
Investigations comparing the effectiveness between myotomy and CABG in patients with symptomatic myocardial bridges consist of one study on 31 patients (4,54) and an even smaller series of 11 patients (55) . In the first investigation, one myotomy case was converted to CABG after accidental right ventricular wall perforation. Among 21/31 patients (either myotomy or CABG) who underwent follow-up angiography, all demonstrated restoration of distal coronary blood flow (4). In the second study, 2/11 patients experienced atypical chest pain and were managed medically (55) .
While both myotomy and CABG are reasonable initial choices, it is unclear which procedure is superior. On the one hand, because myotomy attempts to correct the underlying pathology, it may be the treatment of choice for patients who have symptomatic myocardial bridging refractory to medical therapy, ≥75% systolic coronary compression on angiography or evidence of myocardial ischemia or infarction (4). On the other hand, CABG is favored over myotomy in cases of extensive (>25 mm) or deep (>5 mm) myocardial bridges (the risk of myotomy can be considerable), or when the bridged coronary segment fails to decompress completely in diastole (myotomy is unlikely to correct the persistent diastolic compression) (4, 8) . Importantly, there are no randomized clinical trials comparing intensification of medical therapy to surgical intervention. These limited data suggest that surgical therapy, either myotomy or CABG, appears safe and effective in symptomatic patients with myocardial bridging who are refractory to medical therapy.
Conclusion
Patients with myocardial bridging are commonly encountered clinically who may present with exertional symptoms of myocardial ischemia, syncope, and even sudden death. An array of non-invasive and invasive diagnostic modalities that have shed light on the pathophysiology of myocardial bridging can be deployed to evaluate symptomatic patients. Medical therapy with β-blockers and calcium channel blockers remain the mainstay in treatment. For select patients refractory to intensified medical therapy, surgical intervention, or less preferably PCI with DES, can be considered. Larger registries and randomized clinical trials are warranted to shed light on optimal strategies for patients with myocardial bridging refractory to medical therapy.
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